Source: Proactive Investors

Destiny: Destiny Pharma assessing options for XF-73 nasal

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) said it is exploring 'strategic options' to advance the development of XF-73 nasal, a breakthrough gel to prevent...

Read full article »
Destiny's Competitors | Destiny's News | Destiny's Financials
Stay up-to-date with the latest news on Destiny
Annual Revenue
$5.0-25M
Employees
1-25
Chris Tovey's photo - CEO of Destiny

CEO

Chris Tovey

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Destiny